MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Schrodinger Inc

Closed

SectorHealthcare

26.08 2.23

Overview

Share price change

24h

Current

Min

25.27

Max

26.62

Key metrics

By Trading Economics

Income

-2.1M

-40M

Sales

53M

88M

EPS

-0.24

Profit margin

-45.536

Employees

891

EBITDA

48M

-19M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+35.9% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

333M

1.9B

Previous open

23.85

Previous close

26.08

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Schrodinger Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Nov 2024, 11:55 UTC

Top News

Schrödinger's Stock Soars 9% As It Enters Collaboration Pact With Novartis For Up To About $2.5 Billion In Payments -- MarketWatch

Peer Comparison

Price change

Schrodinger Inc Forecast

Price Target

By TipRanks

35.9% upside

12 Months Forecast

Average 34.6 USD  35.9%

High 45 USD

Low 31 USD

Based on 6 Wall Street analysts offering 12 month price targets forSchrodinger Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

25.75 / 26.86Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

Strong Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.